Written and maintained by CASRAI Editorial Board
Published
On this page
EARS-Net is the European Antimicrobial Resistance Surveillance Network, the European Union system, coordinated by the European Centre for Disease Prevention and Control (ECDC), that collects routine antimicrobial susceptibility results for eight bacterial pathogens from invasive isolates of blood and cerebrospinal fluid. ECDC describes it as the largest publicly funded system for antimicrobial resistance (AMR) surveillance in Europe, and its data are published through the ECDC Surveillance Atlas of Infectious Diseases.
What EARS-Net is
EARS-Net is a disease network run by ECDC. It started as the European Antimicrobial Resistance Surveillance System (EARSS) in 1998, funded initially by the European Commission’s health and consumer directorate and the Dutch Ministry of Health, Welfare and Sports. On 1 January 2010 ECDC took over administration and coordination, and the system was renamed EARS-Net.
According to ECDC’s network page, the objectives are to collect comparable, representative and accurate AMR data; to analyse temporal and spatial trends; to provide timely data for policy; to encourage the development of national AMR surveillance programmes; and to support the diagnostic accuracy of national laboratories through an annual external quality assessment (EQA) that all reporting laboratories are offered.
The name is easy to confuse with unrelated projects that share the letters “EARS” (hearing tests and audio datasets, for example). In research and public-health writing, EARS-Net always means this ECDC surveillance network. Readers new to the underlying laboratory discipline can start with what bacteriology is.
How the data flow from laboratories to the Atlas
EARS-Net does not run its own laboratories. Member State representatives appointed to the network report routine clinical susceptibility data, drawn from national AMR surveillance programmes and/or laboratory networks. ECDC coordinates the network together with an expert committee of disease-specific contact points. The results are then released in two forms:
- The ECDC Surveillance Atlas of Infectious Diseases. ECDC directs users to select “Antimicrobial resistance” in the Atlas, and the data can be downloaded.
- Annual epidemiological reports. ECDC publishes an annual report on AMR in the EU/EEA based on EARS-Net, reporting resistance estimates and progress against the EU targets.
Because the inputs are routine clinical results rather than a purpose-designed study, the system’s strength is comparability and continuity across countries and years, which is exactly what the EQA and the shared reporting rules are there to protect. Infection-prevention teams that use such outputs alongside local surveillance can see how they fit a wider programme in multidrug-resistant organism prevention programme elements.
Which pathogens and specimens EARS-Net covers
ECDC lists eight bacterial pathogens under EARS-Net: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter species, Streptococcus pneumoniae, Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. Only invasive isolates are included, meaning those from blood and cerebrospinal fluid.
The mix of isolates matters when reading any aggregate figure. In the 2022 annual report, ECDC recorded 392,602 isolates (366,794 in 2021), and every EU/EEA country reported for the first time. The share of 2022 isolates by species was as follows.
| Species (2022) | Share of reported isolates |
|---|---|
| E. coli | 39.2% |
| S. aureus | 22.1% |
| K. pneumoniae | 12.3% |
| E. faecalis | 8.2% |
| P. aeruginosa | 6.1% |
| E. faecium | 5.9% |
| S. pneumoniae | 3.7% |
| Acinetobacter spp. | 2.5% |
Two species, E. coli and S. aureus, account for just over 61% of the isolates. A pooled statistic that mixes species will therefore be dominated by them, so analyses are normally done per pathogen and per resistance phenotype rather than across the whole database.
EU 2030 targets and the latest results
A Council Recommendation of 13 June 2023 (2023/C 220/01) set 2030 targets for bloodstream infections measured against a 2019 baseline: a 15% reduction in the incidence of meticillin-resistant S. aureus (MRSA), a 10% reduction for third-generation-cephalosporin-resistant E. coli (3GC-resistant), and a 5% reduction for carbapenem-resistant K. pneumoniae. ECDC’s annual reports track EARS-Net estimates against these targets. The data table below compiles the 2023 and 2024 report figures side by side.
Three points stand out when the two reports are read together:
- MRSA. The estimated incidence was below the target in both reports, with a statistically significant decrease versus 2019 in the 2023 report.
- 3GC-resistant E. coli. It moved from 3.6% below the 2019 level in the 2023 report to 5.9% above it in the 2024 report, and it sat above the target in both. The 2023 report found no statistically significant trend.
- Carbapenem-resistant K. pneumoniae. It was the furthest from its target in both reports, rising from 57.5% above the 2019 level to 61.0% above it. The 2023 report described a statistically significant increasing trend.
Note that the target value for the same indicator differs between the two reports (for example 2.39 versus 2.07 per 100,000 for carbapenem-resistant K. pneumoniae), so compare each estimate with the target printed in the same report rather than with the other year’s figure. ECDC’s 2023 report concluded that it is unlikely the EU will reach all its AMR targets by 2030, and cites an estimated more than 35,000 deaths per year in the EU/EEA from infections with resistant bacteria, based on 2020 data.
The 2023 report also shows how uneven the picture is between countries: the country range for MRSA incidence was 0 to 15.5 per 100,000, for 3GC-resistant E. coli 0 to 19.56, and for carbapenem-resistant K. pneumoniae 0.00 to 21.44. An EU-level figure is a summary across countries, not a typical national value.
EARS-Net compared with other WHO and regional systems
EARS-Net is one of several regional systems that feed or align with the World Health Organization’s Global Antimicrobial Resistance and Use Surveillance System (GLASS). WHO states that GLASS was launched on 22 October 2015, was endorsed by World Health Assembly resolution WHA68.7, and is the first global collaborative effort to standardise AMR surveillance.
| System | Scope as stated by WHO or ECDC |
|---|---|
| EARS-Net (ECDC) | EU/EEA countries; eight bacterial pathogens; invasive isolates from blood and cerebrospinal fluid only |
| CAESAR (WHO) | WHO European Region countries that are not part of EARS-Net |
| ReLAVRA (Latin America) | Regional network, launched 1996 |
| WPRACSS (Western Pacific) | Antimicrobial consumption surveillance, launched 2020 |
| GLASS (WHO) | Global standardising programme that works with CAESAR, EARS-Net, ReLAVRA and WPRACSS |
The practical consequence is that EARS-Net figures describe the EU/EEA, while data on other WHO European Region countries come through a different WHO network. Pooling the two requires checking that case definitions and reporting rules line up.
Where it matters for laboratories, clinics and research
For microbiology laboratories, EARS-Net sets the framework in which routine susceptibility results become national and European data, including the annual EQA offered to reporting laboratories. For infection preventionists, the network supplies the national and EU benchmarks against which local trends are read; see the guide to the infection preventionist role for how that surveillance work sits within a hospital programme. For researchers, the downloadable Atlas data are a ready source of time series by country, pathogen and resistance phenotype, and the annual reports state the definitions behind each indicator. For learned-society context on clinical microbiology and infectious diseases in Europe, see ESCMID.
What EARS-Net does not tell you
- It is not a count of all infections. Only invasive isolates from blood and cerebrospinal fluid are included, so urinary, respiratory, wound and other infections do not appear.
- It covers eight pathogens. Other organisms of clinical or research interest are outside its scope.
- It is not an antimicrobial-consumption system. WHO’s listing of WPRACSS as a consumption system in the Western Pacific illustrates that use and resistance are tracked as separate streams.
- It is geographically bounded. It reports on EU/EEA countries, and the 2024 report is described as covering EU/EEA countries reporting to EARS-Net.
Common misunderstandings
Treating the incidence estimates as raw case counts
The target indicators in the annual reports are estimated incidences per 100,000 population, not counts of isolates. Isolate counts, such as the 392,602 in 2022, are a different quantity: they measure how many laboratory results were reported, not how many people were infected.
Assuming a falling pooled figure means resistance is falling everywhere
The 2023 and 2024 reports show opposite directions for different pathogen and resistance combinations at the same time. MRSA fell while carbapenem-resistant K. pneumoniae rose. Read each indicator separately.
Confusing EARS-Net with GLASS
GLASS is the WHO global programme; EARS-Net is the ECDC network for the EU/EEA, one of the regional systems WHO works with.
Confusing EARS-Net with EARSS
EARSS was the earlier system, established in 1998. ECDC took over coordination on 1 January 2010 and renamed it EARS-Net, so older literature may cite EARSS for the same lineage of data.
Sources
- ECDC: European Antimicrobial Resistance Surveillance Network (EARS-Net), checked 2026-11-16
- ECDC: Surveillance of antimicrobial resistance in Europe, 2022 data, checked 2026-11-16
- ECDC: Antimicrobial resistance in the EU/EEA (EARS-Net), Annual Epidemiological Report for 2023, checked 2026-11-16
- ECDC: Antimicrobial resistance in the EU/EEA (EARS-Net), Annual Epidemiological Report for 2024, checked 2026-11-16
- World Health Organization: Global Antimicrobial Resistance and Use Surveillance System (GLASS), checked 2026-11-16
Data: EARS-Net estimated EU incidence of three target resistant bloodstream infections vs 2030 targets, 2023 and 2024 reports
Compiled from ECDC's EARS-Net Annual Epidemiological Reports for 2023 and 2024: estimated EU/EEA incidence of MRSA, third-generation-cephalosporin-resistant E. coli and carbapenem-resistant K. pneumoniae bloodstream infections, change versus the 2019 baseline, and the 2030 target stated in each report. Targets differ between reports and are given as printed.
Period covered: 2019/2024. Coverage: EU/EEA.
| Indicator | 2023 incidence (per 100,000 population) | 2023 change vs 2019 (%) | 2023 report target (per 100,000 population) | 2024 incidence (per 100,000 population) | 2024 change vs 2019 (%) | 2024 report target (per 100,000 population) |
|---|---|---|---|---|---|---|
| MRSA bloodstream infections | 4.64 | -17.6 | 4.79 | 4.48 | -20.4 | 4.79 |
| 3GC-resistant E. coli bloodstream infections | 10.35 | -3.6 | 9.67 | 11.03 | 5.9 | 9.38 |
| Carbapenem-resistant K. pneumoniae bloodstream infections | 3.97 | 57.5 | 2.39 | 3.51 | 61 | 2.07 |
Sources
- ECDC: Antimicrobial resistance in the EU/EEA (EARS-Net), Annual Epidemiological Report for 2023 (accessed 2026-11-16)
- ECDC: Antimicrobial resistance in the EU/EEA (EARS-Net), Annual Epidemiological Report for 2024 (accessed 2026-11-16)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







